Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magnetic pulses may reignite motivation in memory-loss veterans

NCT ID NCT03590327

Symptom relief Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether transcranial magnetic stimulation (TMS) can reduce apathy—a severe lack of motivation—in older veterans with mild cognitive impairment (MCI). About 103 participants received either real or fake TMS over 20 sessions. The goal was to see if TMS could improve motivation, memory, and daily function, and to identify who responds best using genetic and biomarker tests. The study also explored how the COVID-19 pandemic affected these veterans and their caregivers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

103 people

The number who actually took part.

Started

Nov 2018

Finished

Oct 2024

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * meeting the modified Mayo Clinic criteria for MCI * Having caregivers * apathy threshold (NPI) * MMSE 23 * On stable dose of antidepressants for at least a month (if applicable) Exclusion Criteria: PHASE I * Uncontrolled diabetes mellitus (Fasting BS\>200mg/dl, HbA1c\>10) * Renal disease requiring dialysis * Uncontrolled blood pressure (\>160/100, \<100 systolic) * Metastatic cancer or undergoing chemotherapy * Deep venous thrombosis or myocardial infarction in past 3 months * Uncontrolled malignant cardiac arrhythmia * Cerebral aneurysm or intracranial bleed in past year * Unstable angina in past month * Unstable abdominal or thoracic aortic aneurysm (\>4cm) * End-stage congestive heart failure EXCLUSIONARY DUE TO rTMS: ALL PHASE II AND SUBSET OF PHASE I THAT RECEIVE SINGLE SESSION rTMS * Taking medications known to increase risk of seizures from 2012 Beers criteria such as bupropion, chlorpromazine, clozapine. * Taking other medications known to increase risk of seizures such as tricyclic antidepressants. * Taking ototoxic medications: Aminoglycosides, Cisplatin * History of seizures/ seizures in first degree relatives * Those with implanted device * History of stroke, aneurysm, or cranial neurosurgery * History of bipolar disorder * Current alcohol related disorder needing medical treatment * History of Tourette's syndrome or presence of motor tics * History of abnormal electroencephalogram (EEG) EXCLUSIONARY DUE TO CONFOUNDING WITH APATHY: PHASE II * Current episode of Major Depressive Disorder * Current use of stimulants * Change in dose of dementia medications within 30 days * Change in dose of antidepressants within 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APATHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction COVID-19 Lethargy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APATHY COVID Loneliness Mild cognitive impairment Neuropsychiatric symptoms Transcranial magnetic stimulation

Contacts and locations

Locations

  • Central Arkansas Veterans Healthcare System , Little Rock, AR

    Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.